We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Buys Mesa Biotech, Grows in Point of Care
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) recently completed the acquisition of point-of-care molecular diagnostic company, Mesa Biotech. The agreement, which was announced in January, is worth $550 million.
Mesa Biotech at a Glance
Mesa Biotech’s PCR-based rapid point-of-care testing platform detects infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. As per claim, this patented technology expands the availability of gold standard nucleic acid PCR amplification to point-of-care diagnostics.
Mesa’s Accula Flu A/Flu B, RSV and Strep A tests have already obtained FDA’s 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waivers. The Accula System also received EUA from the FDA for SARS-CoV-2 in-vitro diagnostic testing and is now available for use in patient care settings. According to the report, it, while providing results within 30 minutes, claims to have higher accuracy than other rapid tests on the market.
Strategic Significance
According to Thermo Fisher, this acquisition remains part of the company’s recent efforts to expand foothold in the field of molecular diagnostics at the point of care. Mesa's point-of-care platform will help the company to rapidly scale manufacturing volume, drive cost efficiencies and bring diagnostic testing to market faster and at greater scale.
Mesa Biotech, which had 2020 revenues of approximately $45 million, will become part of the Life Sciences Solution Segment of Thermo Fisher.
Thermo Fisher’s COVID-19 Progress So Far
In 2020, Thermo Fisher’s COVID-19 testing revenues accelerated as customer demand for sample preparation, PCR solutions and viral transport media remained robust. This resulted in generating $6.6 billion of COVID-19 response revenues. In response to the pandemic, the company gained regulatory approval to launch the TaqPath COVID-19 combo kit in March 2020, providing gold standard PCR-based test for customers at an unprecedented scale. The company also significantly expanded its portfolio of COVID-19-related products, including Amplitude solution for high-throughput PCR-based testing and TaqCheck PCR test for asymptomatic health surveillance. In addition, it launched a number of advanced products across base business to strengthen leading positions in analytical instruments, biosciences and bioproduction.
According to the company, its COVID-19 testing has reached an unprecedented level, creating a market-leading molecular diagnostics business in just a few months to support hundreds of millions of PCR tests around the world. The company is also actively engaged in projects to help, develop and produce vaccines and therapies. By the end of 2020, this led to $500 million in COVID-19 vaccine therapy revenues and the company expects this to increase to $1 billion in 2021.
Price Performance
Over the past six months, shares of the company have dipped 3.4% compared with the industry’s 1.4% fall.
Zacks Rank and Key Picks
Currently, Thermo Fisher carries a Zacks Rank #3 (Hold).
Meridian Biosciences has a projected long-term earnings growth rate of 61%.
Owens & Minor has a projected long-term earnings growth rate of 45%.
Envista has an expected long-term earnings growth rate of 24%.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Image: Shutterstock
Thermo Fisher (TMO) Buys Mesa Biotech, Grows in Point of Care
Thermo Fisher Scientific (TMO - Free Report) recently completed the acquisition of point-of-care molecular diagnostic company, Mesa Biotech. The agreement, which was announced in January, is worth $550 million.
Mesa Biotech at a Glance
Mesa Biotech’s PCR-based rapid point-of-care testing platform detects infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. As per claim, this patented technology expands the availability of gold standard nucleic acid PCR amplification to point-of-care diagnostics.
Mesa’s Accula Flu A/Flu B, RSV and Strep A tests have already obtained FDA’s 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waivers. The Accula System also received EUA from the FDA for SARS-CoV-2 in-vitro diagnostic testing and is now available for use in patient care settings. According to the report, it, while providing results within 30 minutes, claims to have higher accuracy than other rapid tests on the market.
Strategic Significance
According to Thermo Fisher, this acquisition remains part of the company’s recent efforts to expand foothold in the field of molecular diagnostics at the point of care. Mesa's point-of-care platform will help the company to rapidly scale manufacturing volume, drive cost efficiencies and bring diagnostic testing to market faster and at greater scale.
Mesa Biotech, which had 2020 revenues of approximately $45 million, will become part of the Life Sciences Solution Segment of Thermo Fisher.
Thermo Fisher’s COVID-19 Progress So Far
In 2020, Thermo Fisher’s COVID-19 testing revenues accelerated as customer demand for sample preparation, PCR solutions and viral transport media remained robust. This resulted in generating $6.6 billion of COVID-19 response revenues. In response to the pandemic, the company gained regulatory approval to launch the TaqPath COVID-19 combo kit in March 2020, providing gold standard PCR-based test for customers at an unprecedented scale. The company also significantly expanded its portfolio of COVID-19-related products, including Amplitude solution for high-throughput PCR-based testing and TaqCheck PCR test for asymptomatic health surveillance. In addition, it launched a number of advanced products across base business to strengthen leading positions in analytical instruments, biosciences and bioproduction.
According to the company, its COVID-19 testing has reached an unprecedented level, creating a market-leading molecular diagnostics business in just a few months to support hundreds of millions of PCR tests around the world. The company is also actively engaged in projects to help, develop and produce vaccines and therapies. By the end of 2020, this led to $500 million in COVID-19 vaccine therapy revenues and the company expects this to increase to $1 billion in 2021.
Price Performance
Over the past six months, shares of the company have dipped 3.4% compared with the industry’s 1.4% fall.
Zacks Rank and Key Picks
Currently, Thermo Fisher carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Meridian Biosciences Inc. , Owens & Minor, Inc. (OMI - Free Report) and Envista Holdings Corporation (NVST - Free Report) , each carrying a Zacks Rank #1 (Strong Buy). You can seethe complete list of Zacks #1 Rank stocks here.
Meridian Biosciences has a projected long-term earnings growth rate of 61%.
Owens & Minor has a projected long-term earnings growth rate of 45%.
Envista has an expected long-term earnings growth rate of 24%.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>